HK1155939A1 - 凝血因子 聚合物偶聯物 - Google Patents

凝血因子 聚合物偶聯物

Info

Publication number
HK1155939A1
HK1155939A1 HK11109099.8A HK11109099A HK1155939A1 HK 1155939 A1 HK1155939 A1 HK 1155939A1 HK 11109099 A HK11109099 A HK 11109099A HK 1155939 A1 HK1155939 A1 HK 1155939A1
Authority
HK
Hong Kong
Prior art keywords
viii
polymer conjugates
factor
factor viii
conjugates
Prior art date
Application number
HK11109099.8A
Other languages
English (en)
Inventor
Peter Turecek
Juergen Siekmann
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1155939(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of HK1155939A1 publication Critical patent/HK1155939A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HK11109099.8A 2008-08-01 2011-08-29 凝血因子 聚合物偶聯物 HK1155939A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/184,567 US7645860B2 (en) 2006-03-31 2008-08-01 Factor VIII polymer conjugates
PCT/US2009/052103 WO2010014708A2 (en) 2008-08-01 2009-07-29 Factor viii polymer conjugates

Publications (1)

Publication Number Publication Date
HK1155939A1 true HK1155939A1 (zh) 2012-06-01

Family

ID=41404469

Family Applications (3)

Application Number Title Priority Date Filing Date
HK11109099.8A HK1155939A1 (zh) 2008-08-01 2011-08-29 凝血因子 聚合物偶聯物
HK15109573.9A HK1208876A1 (zh) 2008-08-01 2011-08-29 凝血因子 聚合物偶聯物
HK15110991.1A HK1210050A1 (zh) 2008-08-01 2011-08-29 凝血因子 聚合物偶聯物

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK15109573.9A HK1208876A1 (zh) 2008-08-01 2011-08-29 凝血因子 聚合物偶聯物
HK15110991.1A HK1210050A1 (zh) 2008-08-01 2011-08-29 凝血因子 聚合物偶聯物

Country Status (22)

Country Link
US (12) US7645860B2 (zh)
EP (3) EP2318050B1 (zh)
JP (1) JP2013500238A (zh)
KR (3) KR101681574B1 (zh)
CN (3) CN104645347A (zh)
AR (1) AR119287A2 (zh)
AU (1) AU2009276625B2 (zh)
BR (1) BRPI0916675B1 (zh)
CA (1) CA2730714C (zh)
CY (1) CY1115801T1 (zh)
DK (2) DK2810662T3 (zh)
ES (2) ES2524598T3 (zh)
HK (3) HK1155939A1 (zh)
HR (1) HRP20141083T1 (zh)
MX (2) MX2011001238A (zh)
NZ (2) NZ590569A (zh)
PL (2) PL2318050T3 (zh)
PT (1) PT2318050E (zh)
SI (1) SI2318050T1 (zh)
SM (1) SMT201500014B (zh)
TW (1) TWI619510B (zh)
WO (1) WO2010014708A2 (zh)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4674702B2 (ja) 2003-04-09 2011-04-20 バイオジェネリクス エージー グリコペギレ−ション法およびその方法により生成されたタンパク質/ペプチド
WO2005012484A2 (en) * 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
EP1824988B1 (en) * 2004-11-12 2017-04-19 Bayer HealthCare LLC Site-directed modification of fviii
JP4951527B2 (ja) * 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖peg化顆粒球コロニー刺激因子
US20070154992A1 (en) * 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
EP2010222A1 (en) 2006-03-31 2009-01-07 Baxter International Inc. Pegylated factor viii
CN101516388B (zh) * 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
JP2010505874A (ja) * 2006-10-03 2010-02-25 ノヴォ ノルディスク アー/エス ポリペプチドコンジュゲートの精製方法
MX2009003470A (es) * 2006-10-04 2009-04-14 Novo Nordisk As Azucares y glicopeptidos pegilados enlazados a glicerol.
US8637007B2 (en) 2006-12-15 2014-01-28 Baxter International Inc. Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life
ES2406267T3 (es) * 2007-04-03 2013-06-06 Biogenerix Ag Métodos de tratamiento usando G-CSF glicopegilado
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US20100286067A1 (en) * 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
AU2009219232B2 (en) 2008-02-27 2014-02-27 Novo Nordisk A/S Conjugated Factor VIII molecules
EP2349342B1 (en) * 2008-10-17 2018-06-27 Baxalta GmbH Modified blood factors comprising a low degree of water soluble polymer
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
KR102068133B1 (ko) * 2009-07-27 2020-01-20 박스알타 인코퍼레이티드 혈액 응고 단백질 복합체
EP3081233B1 (en) * 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
WO2011101242A1 (en) * 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
LT2598172T (lt) * 2010-07-30 2019-08-26 Baxalta GmbH Nukleofiliniai katalizatoriai, skirti oksiminei jungčiai sudaryti
EP3466968A1 (en) 2010-09-15 2019-04-10 Stichting Sanquin Bloedvoorziening Factor viii variants having a decreased cellular uptake
PT2654794T (pt) 2010-12-22 2020-06-11 Baxalta Inc Materiais e métodos para conjugação de um derivado de ácido gordo solúvel em água a uma proteína
CA3012117A1 (en) 2011-05-27 2012-12-06 Baxalta Incorporated Fusions of psa with serpins and other therapeutic proteins
IN2014CN02448A (zh) 2011-09-23 2015-06-19 Novo Nordisk As
CN102584933A (zh) * 2012-02-13 2012-07-18 汪志友 一种利用亲和双水相系统提高凝血因子ⅷ及其类似物分离效率、纯度与生物比活性的方法
EP3564260B1 (en) 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
MX2014013508A (es) * 2012-05-14 2015-02-10 Novo Nordisk As Soluciones proteinicas estabilizadas.
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
GB201210770D0 (en) * 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
RS59124B1 (sr) 2013-04-18 2019-09-30 Novo Nordisk As Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子viii-xten融合物及其用途
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
PL3177317T3 (pl) 2014-08-04 2020-07-27 Csl Limited Formulacja czynnika viii
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
JP2015155469A (ja) * 2015-06-01 2015-08-27 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 第fviii因子ポリマー結合体
EP3331608A4 (en) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME
TW201731869A (zh) 2015-12-03 2017-09-16 百克莎塔股份有限公司 具有延長之半衰期及降低之配位體結合性質的因子viii
MA45473A (fr) 2016-04-04 2019-02-13 Shire Human Genetic Therapies Inhibiteur de c1 estérase conjugué et ses utilisations
AU2017296195A1 (en) 2016-07-11 2019-01-24 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
CN108267590B (zh) * 2016-12-31 2021-05-11 江苏众红生物工程创药研究院有限公司 Peg修饰蛋白的peg结合数检测方法
CN107349459B (zh) * 2017-06-16 2019-11-26 大连理工大学 一种葡聚糖基止血抗菌促愈合材料及其制备方法
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
JP2018115170A (ja) * 2018-03-02 2018-07-26 バクスアルタ ゲーエムベーハー 第fviii因子ポリマー結合体
BR112020023168A2 (pt) * 2018-05-18 2021-02-09 Zhengzhou Gensciences Inc. proteína de fusão de fviii aprimorada e uso da mesma
WO2020099513A1 (en) 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
AU591671B2 (en) 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
US5250421A (en) * 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
CA1339946C (en) 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5252421A (en) * 1988-07-18 1993-10-12 Fuji Xerox Co., Ltd. Electrophotographic toner
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
SE466754B (sv) * 1990-09-13 1992-03-30 Berol Nobel Ab Saett att kovalent binda biopolymerer till hydrofila ytor
US5492821A (en) * 1990-11-14 1996-02-20 Cargill, Inc. Stabilized polyacrylic saccharide protein conjugates
CA2101918A1 (en) 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
MX9203763A (es) 1991-06-28 1993-08-01 Rhone Poulenc Rorer Int Polipeptidos terapeuticos a base del factor de von willebrand
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
DE69329795T2 (de) * 1992-10-02 2001-07-05 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
FR2700268B1 (fr) 1993-01-13 1995-03-31 Lvmh Rech Composition cosmétique ou pharmaceutique, notamment dermatologique, contenant un extrait de Vismia.
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US5700873A (en) * 1995-03-07 1997-12-23 Adhesives Research, Inc. Method of preparation of water-soluble copolymer
US6127153A (en) 1995-06-07 2000-10-03 Neose Technologies, Inc. Method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and gene encoding a polyglycosyltransferase
WO1996040731A1 (en) 1995-06-07 1996-12-19 Mount Sinai School Of Medicine Of The City University Of New York Pegylated modified proteins
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
AT405740B (de) 1996-12-13 1999-11-25 Immuno Ag Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
WO1998048837A1 (en) * 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
EP1012259B1 (en) * 1997-06-04 2009-09-30 Oxford Biomedica (UK) Limited Tumor targeted vector
AU2855499A (en) 1998-03-24 1999-10-18 Nof Corporation Oxirane derivatives and process for producing the same
EP2599503B1 (en) 1998-10-16 2017-05-17 Biogen MA Inc. Polymer conjugates of interferon beta-1A and uses thereof
DE19852729A1 (de) * 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
AT407750B (de) 1999-02-19 2001-05-25 Immuno Ag Verfahren zur herstellung einer vwf-präparation
BR0008405B1 (pt) 1999-02-22 2014-04-22 Baxter Int Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
WO2001005434A2 (en) 1999-07-20 2001-01-25 Amgen Inc. Hyaluronic acid-protein conjugates
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7230081B1 (en) * 1999-11-12 2007-06-12 Maxygen Holdings, Ltd. Interferon gamma conjugates
SE515295C2 (sv) 1999-11-23 2001-07-09 Medicarb Ab Förfarande för framställning av konjugat av en biologiskt aktiv polysackarid och ett fast substrat, samt sådana konjugat
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP1982732A3 (en) * 2000-02-11 2011-06-08 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
DE60137525D1 (de) 2000-10-16 2009-03-12 Chugai Pharmaceutical Co Ltd Peg-modifiziertes erythropoietin
AUPR610501A0 (en) 2001-07-04 2001-07-26 Smart Drug Systems Inc Treatment of parasitic disease
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
JP5232352B2 (ja) * 2001-10-10 2013-07-10 ノボ ノルデイスク エイ エス ペプチドの改造および複合糖質化
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7026440B2 (en) 2001-11-07 2006-04-11 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US6473908B1 (en) * 2002-01-09 2002-11-05 Thomas A. Bontems Garment having a buttocks cleavage revealing feature
EP2572732A1 (en) * 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
RU2333223C2 (ru) 2003-08-12 2008-09-10 Лайпоксен Текнолоджиз Лимитед Альдегидные производные сиаловой кислоты, способы их получения, конъюгаты альдегидных производных сиаловой кислоты и фармацевтическая композиция на их основе
DE602004009314T2 (de) 2003-08-12 2008-02-07 Lipoxen Technologies Ltd. Polysialinsäurederivate
WO2005032581A2 (en) 2003-10-07 2005-04-14 Novo Nordisk Health Care Ag Hybrid molecules having factor vii/viia activity
CA2549011A1 (en) 2003-12-10 2005-06-30 Nektar Therapeutics Al, Corporation Compositions comprising two different populations of polymer-active agent conjugates
WO2006016161A1 (en) 2004-08-12 2006-02-16 Lipoxen Technologies Limited Fractionation of charged polysaccharide
EP3184551A1 (en) 2004-08-12 2017-06-28 Lipoxen Technologies Limited Sialic acid derivatives
JP5022231B2 (ja) * 2004-12-27 2012-09-12 バクスター・インターナショナル・インコーポレイテッド ポリマー−フォンビルブラント因子結合体
EP1896082B1 (en) 2005-06-16 2012-12-26 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
EP2010222A1 (en) * 2006-03-31 2009-01-07 Baxter International Inc. Pegylated factor viii
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP2059527B1 (en) * 2006-09-01 2014-12-03 Novo Nordisk Health Care AG Modified glycoproteins
US8637007B2 (en) * 2006-12-15 2014-01-28 Baxter International Inc. Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
TW201731869A (zh) 2015-12-03 2017-09-16 百克莎塔股份有限公司 具有延長之半衰期及降低之配位體結合性質的因子viii

Also Published As

Publication number Publication date
US20190183981A1 (en) 2019-06-20
US8003760B2 (en) 2011-08-23
CN102112156A (zh) 2011-06-29
US20100173830A1 (en) 2010-07-08
KR20180083447A (ko) 2018-07-20
US8071724B2 (en) 2011-12-06
PL2318050T3 (pl) 2015-02-27
BRPI0916675B1 (pt) 2021-06-01
EP2799088B1 (en) 2021-03-24
DK2810662T3 (da) 2021-06-21
US20110112025A1 (en) 2011-05-12
US20110206651A1 (en) 2011-08-25
ES2877852T3 (es) 2021-11-17
HK1210050A1 (zh) 2016-04-15
US8071725B2 (en) 2011-12-06
US20100173831A1 (en) 2010-07-08
AU2009276625B2 (en) 2014-10-30
JP2013500238A (ja) 2013-01-07
WO2010014708A3 (en) 2010-04-22
EP2810662A1 (en) 2014-12-10
KR20110039364A (ko) 2011-04-15
US20110112024A1 (en) 2011-05-12
DK2318050T3 (da) 2014-11-10
US7985838B2 (en) 2011-07-26
NZ590569A (en) 2012-12-21
US20160058842A1 (en) 2016-03-03
AR119287A2 (es) 2021-12-09
CN102112156B (zh) 2015-01-28
TWI619510B (zh) 2018-04-01
EP2318050B1 (en) 2014-09-03
KR101879838B1 (ko) 2018-07-19
ES2524598T3 (es) 2014-12-10
US20140024808A1 (en) 2014-01-23
US20120232252A1 (en) 2012-09-13
NZ603269A (en) 2014-09-26
US20090076237A1 (en) 2009-03-19
US8071728B2 (en) 2011-12-06
EP2799088A2 (en) 2014-11-05
MX2011001238A (es) 2011-03-29
BRPI0916675A2 (pt) 2015-11-17
PL2810662T3 (pl) 2021-12-13
CN104645347A (zh) 2015-05-27
EP2318050A2 (en) 2011-05-11
MX2020006187A (es) 2020-09-03
CN104479006A (zh) 2015-04-01
US20110112026A1 (en) 2011-05-12
US11020458B2 (en) 2021-06-01
WO2010014708A2 (en) 2010-02-04
EP2799088A3 (en) 2014-12-10
HK1208876A1 (zh) 2016-03-18
SMT201500014B (it) 2015-03-05
HRP20141083T1 (hr) 2015-01-02
KR20160140975A (ko) 2016-12-07
KR102049190B1 (ko) 2019-11-26
CA2730714A1 (en) 2010-02-04
AU2009276625A8 (en) 2011-03-03
US20170157259A1 (en) 2017-06-08
KR101681574B1 (ko) 2016-12-01
TW201010731A (en) 2010-03-16
CY1115801T1 (el) 2017-01-25
AU2009276625A1 (en) 2010-02-04
PT2318050E (pt) 2014-12-02
CA2730714C (en) 2013-10-08
US8067543B2 (en) 2011-11-29
US7645860B2 (en) 2010-01-12
SI2318050T1 (sl) 2015-01-30
EP2810662B1 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
HK1210050A1 (zh) 凝血因子 聚合物偶聯物
IL211180B (en) Attached polyethylene glycol and docetaxel
ZA201005556B (en) Conjugated factor viii molecules
EP2271359A4 (en) CAMPTOTHECINBINDING REST CONJUGATES
EP2209552A4 (en) TONE-NETWORKED POLYMER YELLOW
HK1160874A1 (zh) 可生物降解的聚合物組合物
GB2450587B (en) Polymer composition
GB0901103D0 (en) Polymer composition
GB0711188D0 (en) Polymer Nanocomposite
EG25972A (en) Polymer composition
GB0815883D0 (en) Polymer blends
GB0806086D0 (en) Dendrimer polymer hybrids
EP2284220A4 (en) POLYMER COMPOSITION
EP2358763A4 (en) POLYMER COMPOSITION
EP2151477A4 (en) POLYMER COMPOSITION
PL2350139T3 (pl) Polimer multimodalny
IL199718A0 (en) Peptide-complement conjugates
GB0711120D0 (en) Polymer components
GB0922354D0 (en) Novel polymer conjugates
HK1158236A1 (zh) 肽-聚合物綴合物
HUS1900042I1 (hu) Konjugált VIII-as faktor molekulák
GB0823437D0 (en) Polymer composition
GB0718456D0 (en) Molecular knex-structures
GB0724985D0 (en) Molecular KNEX-structures
GB0801988D0 (en) Nanoparticle conjugates